{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:28:46Z","timestamp":1790494126367,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1002\/jps.22742","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T11:32:29Z","timestamp":1315567949000},"page":"31-47","source":"Crossref","is-referenced-by-count":88,"title":["Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine"],"prefix":"10.1016","volume":"101","author":[{"given":"Sheena H.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M.","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soman N.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman F.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1002\/jps.22742_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/20014091096738","article-title":"Anthrax toxin","volume":"27","author":"Bhatnagar","year":"2001","journal-title":"Crit Rev Microbiol"},{"issue":"4","key":"10.1002\/jps.22742_bb0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0736-4679(03)00079-9","article-title":"The history of anthrax","volume":"24","author":"Sternbach","year":"2003","journal-title":"J Emerg Med"},{"issue":"10","key":"10.1002\/jps.22742_bb0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1002\/jps.22742_bb0025","first-page":"335","article-title":"Anthrax: Clinical features, pathogenesis, and potential biological warfare threat","volume":"20","author":"Friedlander","year":"2000","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1002\/jps.22742_bb0030","series-title":"Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices","author":"CDC","year":"2000"},{"issue":"10","key":"10.1002\/jps.22742_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J Med Microbiol"},{"issue":"Pt 6","key":"10.1002\/jps.22742_bb0040","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"issue":"11","key":"10.1002\/jps.22742_bb0045","first-page":"e13849","volume":"5","author":"Brown","year":"2010","journal-title":"Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults"},{"issue":"4","key":"10.1002\/jps.22742_bb0050","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"issue":"2","key":"10.1002\/jps.22742_bb0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1002\/jps.22742_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14760584.5.4.417","article-title":"Recombinant protective antigen 102 (rPA102): Profile of a second-generation anthrax vaccine","volume":"5","author":"Keitel","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"33\u201334","key":"10.1002\/jps.22742_bb0065","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"issue":"1\u20133","key":"10.1002\/jps.22742_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(01)00171-5","article-title":"Chitosan as a novel nasal delivery system for vaccines","volume":"51","author":"Illum","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"10.1002\/jps.22742_bb0075","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0264-410X(03)00074-4","article-title":"Novel generations of influenza vaccines","volume":"21","author":"Kemble","year":"2003","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/jps.22742_bb0080","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective mucosal immunity to anthrax: Neutralizing antibodies and Th cell responses following nasal immunization with protective antigen","volume":"170","author":"Boyaka","year":"2003","journal-title":"J Immunol"},{"issue":"21\u201322","key":"10.1002\/jps.22742_bb0085","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1016\/S0264-410X(02)00191-3","article-title":"Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses","volume":"20","author":"Debin","year":"2002","journal-title":"Vaccine"},{"issue":"21\u201322","key":"10.1002\/jps.22742_bb0090","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/S0264-410X(02)00207-4","article-title":"Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin","volume":"20","author":"Gaur","year":"2002","journal-title":"Vaccine"},{"issue":"10","key":"10.1002\/jps.22742_bb0095","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/1521-4141(2002010)32:10<2857::AID-IMMU2857>3.0.CO;2-R","article-title":"The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant","volume":"32","author":"Rharbaoui","year":"2002","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1002\/jps.22742_bb0100","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.4049\/jimmunol.167.9.5386","article-title":"Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization","volume":"167","author":"Staats","year":"2001","journal-title":"J Immunol"},{"issue":"5","key":"10.1002\/jps.22742_bb0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1568026043451230","article-title":"Modulation of the immune response by the cholera-like enterotoxins","volume":"4","author":"Plant","year":"2004","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"10.1002\/jps.22742_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1586\/14760584.2.2.205","article-title":"Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA","volume":"2","author":"Holmgren","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1002\/jps.22742_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.mlg.0000194222.93067.f7","article-title":"Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant","volume":"116","author":"Kodama","year":"2006","journal-title":"Laryngoscope"},{"issue":"9","key":"10.1002\/jps.22742_bb0120","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.165.9.4778","article-title":"Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues","volume":"165","author":"van Ginkel","year":"2000","journal-title":"J Immunol"},{"issue":"2","key":"10.1002\/jps.22742_bb0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni1158","article-title":"Mast cells in the development of adaptive immune responses","volume":"6","author":"Galli","year":"2005","journal-title":"Nat Immunol"},{"issue":"18","key":"10.1002\/jps.22742_bb0130","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1073\/pnas.0501912102","article-title":"Mast cells enhance T cell activation: Importance of mast cell-derived TNF","volume":"102","author":"Nakae","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1002\/jps.22742_bb0135","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.4049\/jimmunol.177.6.3577","article-title":"Dendritic cell modulation by mast cells controls the Th1\/Th2 balance in responding T cells","volume":"177","author":"Mazzoni","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1002\/jps.22742_bb0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: A new class of highly effective vaccine adjuvants","volume":"14","author":"McLachlan","year":"2008","journal-title":"Nat Med"},{"key":"10.1002\/jps.22742_bb0145","doi-asserted-by":"crossref","unstructured":"Staats HF, Fielhauer JR, Thompson AL, Tripp AA, Sobel AE, Maddaloni M, Abraham SN, Pascual DW. Mucosal targeting of a BoNT\/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT\/A neutralizing antibodies in rabbits. PLoS One 6(1):e16532.","DOI":"10.1371\/journal.pone.0016532"},{"issue":"7\u20138","key":"10.1002\/jps.22742_bb0150","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0264-410X(00)00228-0","article-title":"Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine","volume":"19","author":"Anderson","year":"2000","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/jps.22742_bb0155","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1208\/pt0804081","article-title":"Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination","volume":"8","author":"Garmise","year":"2007","journal-title":"AAPS PharmSciTech"},{"issue":"17\u201319","key":"10.1002\/jps.22742_bb0160","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/S0264-410X(00)00503-X","article-title":"A powder formulation of measles vaccine for aerosol delivery","volume":"19","author":"LiCalsi","year":"2001","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/jps.22742_bb0165","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1208\/pt070119","article-title":"Formulation of a dry powder influenza vaccine for nasal delivery","volume":"7","author":"Garmise","year":"2006","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1002\/jps.22742_bb0170","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1002\/jps.22742_bb0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1521-4141(200203)32:3<671::AID-IMMU671>3.3.CO;2-X","article-title":"The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells","volume":"32","author":"Montemurro","year":"2002","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1002\/jps.22742_bb0180","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect Immun"},{"issue":"6","key":"10.1002\/jps.22742_bb0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1016292416526","article-title":"Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures","volume":"12","author":"Hancock","year":"1995","journal-title":"Pharm Res"},{"issue":"10","key":"10.1002\/jps.22742_bb0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3109\/03639049809097269","article-title":"Physicochemical stability of crystalline sugars and their spray-dried forms: Dependence upon relative humidity and suitability for use in powder inhalers","volume":"24","author":"Naini","year":"1998","journal-title":"Drug Dev Ind Pharm"},{"issue":"4","key":"10.1002\/jps.22742_bb0195","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0006-3495(96)79407-9","article-title":"Is trehalose special for preserving dry biomaterials","volume":"71","author":"Crowe","year":"1996","journal-title":"Biophys J"},{"issue":"1","key":"10.1002\/jps.22742_bb0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/abio.1997.2366","article-title":"Correcting the circular dichroism spectra of peptides for contributions of absorbing side chains","volume":"253","author":"Krittanai","year":"1997","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1002\/jps.22742_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2006.08.014","article-title":"Conformational analysis of protein secondary structure during spray-drying of antibody\/mannitol formulations","volume":"65","author":"Schule","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1002\/jps.22742_bb0210","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1021\/ja01172a009","article-title":"Synthetic analogs of oxytocic drugs; phenethyl beta-alanine derivatives","volume":"71","author":"Baltzly","year":"1949","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1002\/jps.22742_bb0215","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/jm00273a026","article-title":"Molecular weight studies on the active constituents of compound 48-80","volume":"15","author":"Read","year":"1972","journal-title":"J Med Chem"},{"issue":"1","key":"10.1002\/jps.22742_bb0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0026-895X(25)11543-5","article-title":"A nuclear magnetic resonance study of compound 48\/80","volume":"15","author":"Ortner","year":"1979","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1002\/jps.22742_bb0225","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1476-5381.1951.tb00661.x","article-title":"Compound 48\/80: A potent histamine liberator","volume":"6","author":"Paton","year":"1951","journal-title":"Br J Pharmacol Chemother"},{"issue":"2\u20133","key":"10.1002\/jps.22742_bb0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(85)90687-9","article-title":"Histamine release induced from mast cells by active components of compound 48\/80","volume":"115","author":"Koibuchi","year":"1985","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1002\/jps.22742_bb0235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0006-2952(83)90522-1","article-title":"Antimicrobial action of compound 48\/80\u2013II mechanism of action","volume":"32","author":"Hall","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/jps.22742_bb0240","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: Receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1002\/jps.22742_bb0245","doi-asserted-by":"crossref","unstructured":"Gwinn WM, Kirwan SM, Wang SH, Ashcraft KA, Sparks NL, Doil CR, Tlusty TG, Casey LS, Hollingshead SK, Briles DE, Dondero RS, Hickey AJ, Foster WM, Staats HF. Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine 28(42):6901\u20136914.","DOI":"10.1016\/j.vaccine.2010.08.006"},{"issue":"1\u20132","key":"10.1002\/jps.22742_bb0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915317639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915317639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:05:49Z","timestamp":1741593949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915317639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0022354915317639"],"URL":"https:\/\/doi.org\/10.1002\/jps.22742","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}